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1607-551X/Copyright ª 2014, KaohsiuAbstract Previous studies have shown that the incidence of diabetes is higher when women
come to menopause. This study was carried out to examine the effects of combined estrogen
replacement therapy (ERT) on diabetes in postmenopausal women. PubMed/MEDLINE was
searched for English-language articles published between January 1997 and June 2011. Studies
that examined ERT on the incidence of diabetes and randomized clinical trials that evaluated
combined ERT (estrogen plus progesterone) on diabetic indices in postmenopausal women
were included. Pooled relative risks were calculated using a random- or a fixed-effects model.
Sixteen studies comprising 17,971 cases were included. Based on the pooled data, ERT signif-
icantly reduced the incidence of diabetes [odds ratio (OR), 0.61; 95% confidence interval (CI),
0.55e0.68, ERT past/current/continuous use vs. never use; OR, 0.57; 95% CI, 0.51e0.65, ERT
current/continuous use vs. past/never use]. Women with combined ERT have significantly
lower levels of fasting plasma glucose (mean difference, e1.41 mM/L; 95% CI, e2.49 to
0.33 mM/L) and HbA1c (mean difference, e0.73%; 95% CI, from 1.28 to 0.18%) compared
with placebo. Furthermore, combined ERT dramatically reduced plasma total cholesterol
(mean difference, e0.34 mM/L; 95% CI, from 0.53 to 0.15 mM/L) and low-density lipopro-
tein (mean difference, e0.43 mM/L; 95% CI, from 0.71 to 0.14 mM/L) but slightly increasedave no conflicts of interest to declare.
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ERT and diabetes in postmenopausal women 351high-density lipoprotein (mean difference, 0.02 mM/L; 95% CI, from 0.07 to 0.12 mM/L)
levels as compared with placebo control. This systemic review and meta-analysis provides ev-
idence that postmenopausal women taking low-dose combined ERT have a decreased risk of
developing diabetes and have better diabetic control.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Diabetes, with long-term consequences including kidney
failure, amputations, genitourinary, and cardiovascular
symptoms, is one of the most common chronic diseases and
a major public health problem [1]. It is estimated that the
number of diabetic patients in the world will double from
171 million in 2000 to 366 million in 2030 [2]. It is therefore
important to identify interventions that can decrease the
risk of diabetes.
Several factors increase the risk of diabetes, including
overweight, physical inactivity, advancing age, and family
history of diabetes [3,4]. There is a growing consensus that
the decline in ovarian hormone levels at the time of
menopause may play a role [5]. Epidemiological studies
found that the ratio of using estrogen in diabetic women
was only about half of that in nondiabetic women [6e10],
and the incidence of diabetes dramatically increased when
women came to the postmenopausal period [2]. A study
reported that the prevalence of diabetes among women
aged 50 years and older was at least 15% in the United
States [11]. It is postulated that the high incidence of dia-
betes in postmenopausal women is due to the imbalance of
endogenous sex hormone levels in that the plasma estrogen
is significantly reduced when women come to the meno-
pausal period. The exact biological mechanism is not fully
understood, but there are several factors that may help to
explain the relationship, including increasing antioxidative
stress and anti-inflammation ability, modulating cholesterol
metabolism [12], or increasing insulin sensitivity [13] by
estrogen. Insulin sensitivity is closely related with the
plasma concentration of estrogen. It is reported previously
that estrogen per se augmented insulin sensitivity at low
concentrations but diminishes insulin sensitivity at high
concentrations when examined on a pregnancy rat model
[14]. There is a report indicating that insulin-stimulated
glucose uptake was improved by estrogen replacement
even in postmenopausal nondiabetic women [15]. Recently,
Bonds and colleagues [16] conducted the Women’s Health
Initiative randomized trial and found that estrogen
replacement therapy (ERT) with conjugated equine estro-
gen possessed protective effects against diabetes.
During the past 2 decades, several studies have evalu-
ated the effect of ERT in postmenopausal women; however,
most of these studies primarily concern women without
diabetes. Moreover, there is discrepancy in the therapy
effect because of the different trial designs used in these
studies. To comprehensively assess the association between
ERT and diabetes in postmenopausal women, we conducted
a meta-analysis to summarize these studies. Previously, a
randomized, double-blind prospective trial concerning15,641 postmenopausal women also identified that com-
bined administration with estrogen plus progestin had
favorable effects on glucose homeostasis [17]. To this end,
we also investigated whether combined ERT could amelio-
rate indices including carbohydrate and lipid metabolism in
postmenopausal diabetic patients.
Methods
Search strategy and selection criteria
A literature searchof PubMed/MEDLINEandEMBASE (January
1997eJune 2011) using the keywords and Medical Subject
Headings diabetes combined with estrogen replacement
therapy was conducted. To be included, studies had to be
written in English in peer-reviewed journals.
Specifically, to evaluate the influence of ERT on the
incidence of diabetes, trials should meet the following
criteria: (1) Involving diabetes (either type 1 or type 2
diabetes mellitus); (2) ERT (single ERT with estradiol only,
or combined ERT with estradiol plus progesterone); (3)
postmenopausal women; and (4) reported with means and
standard deviation (SD; or sufficient data to calculate).
As single ERTs may increase the risk of estrogen-related
disease, combined ERT administration was mostly applied.
To evaluate the therapeutic effects of combined ERT on
diabetic indices,we further sourced trials using the following
criteria: (1) postmenopausal women being diagnosed with
diabetes (either type 1 or type 2 diabetes mellitus) at base-
line; (2) combined oral estrogen plus progesterone adminis-
tration; (3) randomized and placebo-controlled prospective
study; (4) there should be a washout period of at least 4
weeks between treatments for crossover studies; (5) re-
ported diabetic indices including fasting plasma glucose,
glycated hemoglobin (HbA1c), insulin, total cholesterol (TC),
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and triglyceride (TG); and (6) reported with means
and SD (or sufficient data to calculate).
Diabetes is defined as a fasting blood glucose level of
6.9 mM/L (126 mg/dL); patients who are currently taking
antihyperglycemic agents or have a medical history of
diabetes were also included. Postmenopause was the con-
dition if more than 12 months had elapsed since the pa-
tient’s last natural menstruation or if she had experienced
bilateral oophorectomy.
Data extraction
Two investigators (Y.X. and J.L.) independently reviewed the
titles, abstracts, and full articles of theoriginal references for
352 Y. Xu et al.inclusion. Discrepancies in eligibility were discussed between
reviewers until agreement was achieved. Data abstraction
was independently completed by two authors (Y.X. and J.L.)
and compared for accuracy. Information extracted included
lead author, publication year, length of follow-up for pro-
spective study, country in which the study was performed,
protocol design, sample size, and means with SD.
Statistical analysis
The analyses were performed using Review Manager 4.2
software (Cochrane Library Software, Oxford, UK) and STATA
11.0 software (StataCorp, College Station, TX, USA). Odds
ratio (OR) was used as a measure of association between ERT
use status and incidence of diabetes. Specifically, we first
compared the effect of estrogen ever use (including estrogen
continuous, current, and past use) versus never use on dia-
betes incidence in six studies; then, we further evaluated
estrogen continuous/current versus past/never use on dia-
betes. For diabetic indices evaluation, the net treatment
effects for each analysis were pooled to obtain a weighted
mean difference using a fixed- or random-effects model. To
test for interstudy heterogeneity, the Chi-square value was
calculated for the assumption of homogeneity. Publication
bias was evaluated using funnel plot and Egger’s test [18]. All
statistical tests were two-sided, and p< 0.05was considered
statistically significant.
Results
Literature search results
Our search identified a total of 490 potential articles for re-
view, eight of which met our inclusion criteria for evaluating
theassociation betweenERTanddiabetes [19e26], andeight
met the criteria for examining the therapeutic effect of
combined ERT on diabetic indices [27e34] (see Fig. 1 for
study selection flowchart).
Study characteristics
Table 1 displays the characteristics of the eight studies on
evaluating the association between ERT and diabetes: six
studies [19,20,22,23,25,26] were conducted in the United
States, one in The Netherlands [21], and one in Finland [24];
two were prospective trials with a follow-up period ranging
from 5 years to 12 years [19,24], and six were cross-sectional
studies [20e23,25,26]; study sample sizes ranged from491 to
8483, and the total sample size across studies was 16,807.
Table 2 shows the characteristics of the eight studies on
examining the effects of combined ERTon diabetic indices in
postmenopausal women: among the eight trials, two were
crossover studies [27,31]; the follow-up period ranged from3
months to 4.1 years; the study sample sizes ranged from28 to
734, and the total sample size across studies was 1164.
Association between ERT and incidence of diabetes
The between-studies heterogeneity was assessed using the
Chi-square test statistics. The results of the Chi-square testindicated that the studies for evaluating the association
between ERT and the incidence of diabetes had no signifi-
cant heterogeneity (p > 0.05). Thus, we applied the fixed-
effects model to analyze it.
A strong inverse association between ERT and the risk of
diabetes was observed. Overall, ERT significantly decreased
the risk of diabetes in postmenopausal women (p < 0.0001;
Fig. 2A and B). Specifically, ERTever use (including ERT past,
current, and continuous use) significantly reduced the risk as
compared with ERT never use (OR, 0.61; 95% CI, 0.55e0.68;
Fig. 2A). Moreover, ERT continuous/current use has a more
significant protective effect on diabetes as compared with
past/never use (OR, 0.57; 95% CI, 0.51e0.65; Fig. 2B). In the
subgroup analyses, we observed in the prospective studies
that ERT ever (past/current/continuous) use also had a sig-
nificant preventive effect on diabetes in the nondiabetic
population (OR, 0.62; 95% CI, 0.48e0.80) as compared with
that in cross-sectional studies (OR, 0.61; 95% CI, 0.54e0.69;
Fig. 2A); moreover, ERTcurrent/continuous use had a better
protective effect on diabetes in nondiabetic populations
(OR, 0.49; 95% CI, 0.36e0.65) as comparedwith that in cross-
sectional studies (OR, 0.60; 95% CI, 0.52e0.69; Fig. 2B). The
results in subgroup analyses indicated that ERT had a pre-
ventive effect on the new-onset of diabetes. Therefore, ERT
use has favorable effects on the whole postmenopausal
women population from the onset of diabetes.
Egger’s tests suggested no publication bias (p Z 0.205
for Fig. 2 A and p Z 0.194 for Fig. 2B), and the shape of
funnel plots appeared to be symmetrical (Fig. 2C and D).ERT on fasting plasma glucose and HbA1c
As single ERTs may increase the risk of estrogen-related
disease, in the following study, we evaluated the protective
effects of combined ERT use in postmenopausal women
with diabetes and analyzed the changes in parameters
including fasting plasma glucose and HbA1c, body mass
index (BMI), plasma TC, LDL, HDL, and TG levels, which
were closely related to diabetes.
Hyperglycemia is a feature of both type 1 and type 2
diabetes, and it plays a dominant role in the complications
of diabetes. The results of the Chi-square test indicated
that the studies were significantly heterogeneous
(p < 0.05); thus, we applied the random-effects model to
evaluate the effects of ERT on fasting plasma glucose and
HbA1c. The body included 946 postmenopausal diabetic
women from six studies [27e32] for analyzing combined
ERT on fasting plasma glucose and 212 women from five
studies [27,28,30e32] for analyzing combined ERT on
plasma HbA1c. Overall, combined ERT significantly
decreased fasting plasma glucose (mean difference,
e1.41 mM/L; 95% CI, from 2.49 to 0.33 mM/L; Fig. 3A)
and HbA1c (mean difference, e0.73%; 95% CI, from 1.28
to 0.18%; Fig. 3B) compared with patients with placebo.
In this analysis, no publication bias was found as evalu-
ated by Egger’s tests (p Z 0.084 for Fig. 3A and p Z 0.958
for Fig. 3B) and the shape of funnel plots (Fig. 3C and D).
BMI
Obesity has been well known as a risk factor for diabetes.
Studies have found that obesity is strongly associated with
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Figure 1. PRISMA flow diagram for selection of studies in the meta-analysis.
ERT and diabetes in postmenopausal women 353insulin resistance [35]. The results of the Chi-square test
indicated the studies had no significant heterogeneity
(p Z 0.62); thus, we applied the fixed-effects model to
evaluate combined ERT use on the BMI. The body included
147 postmenopausal diabetic women from two studies
[28,33]. It was observed that combined ERT decreased BMI
in postmenopausal women with diabetes (mean differ-
ence, e1.05; 95% CI, e2.79e0.69 kg/m2) compared with
controls (Fig. 4A), but no statistical significance was
found.
As the sample size in BMI evaluation was too small
(nZ 2), Egger’s test could not be carried out; however, the
funnel plot seemed to be symmetrical (Fig. 4B).
TC, LDL, and HDL
Dyslipidemia is one of the major risk factors for cardiovas-
cular disease in diabetes. The characteristic features of
diabetic dyslipidemia are high plasma TG concentration, low
HDL cholesterol concentration, and increased concentration
of small dense LDL cholesterol. The body of TC, LDL, and HDL
studies included 430 postmenopausal diabetic patients from
seven trials [27,28,30e34]. As the results of Chi-square test
indicated that the studies for TC had no significant hetero-
geneity (pZ 0.48) whereas the studies for LDL and HDL had a
significant heterogeneity (p < 0.05); thus, we applied the
fixed- or random-effects model to respectively evaluate theeffects of combined ERT on them. As depicted in Fig. 5A,a
significantly decreased level of TC was suggested among
cases taking combined ERTas comparedwith placebo control
(mean difference, e0.34 mM/L; 95% CI, from 0.53 to
0.15mM/L).Meanwhile, administrationwith combinedERT
significantly decreased LDL (mean difference, e0.43 mM/L;
95% CI, from 0.71 to 0.14 mM/L; Fig. 5B) but slightly
increased HDL (mean difference, 0.02 mM/L; 95% CI, from
0.07 to 0.12 mM/L; Fig. 5C).
In this study, we did not find publication bias as detected
by Egger’s tests (p Z 0.589 for Fig. 5A, p Z 0.452 for
Fig. 5B, and p Z 0.509 for Fig. 5C) and funnel plots
(Fig. 5DeF).
Triglyceride
The body of TG study included 389 cases from six trials
[27,28,31e34]. The results of the Chi-square test indicated
that the studies had no significant heterogeneity
(p Z 0.79); thus, we applied the fixed-effects model to
evaluate the effect of ERT on plasma TG. As shown in
Fig. 6A, the plasma TG level was slightly reduced by ERT
(mean difference, e0.03 mM/L; 95% CI, from 0.26 to
0.20); however, no significant difference was found.
No publication bias was observed during this study as
evaluated by Egger’s test (p Z 0.541) and funnel plot
(Fig. 6B).
Table 1 Study characteristics of the association between ERT and the incidence of diabetes in postmenopausal women.
Source Location Follow-up (y) Design Age (y) Case (n) (total/diabetes)
Never Past ent Never Past Current
Gabal et al. [19] USA 12 Prospective 64.1 (6.6) 61.8 (6.5) 59 6.0) 225/31 374/48 226/24
59 5.7)a 170/17a
Dubuisson et al. [20] USA NA Cross-sectional 60.2 (6)b 59.4 (7)b 58 7)b 319/124 104/34 200/54
58.9 (7)c 57.9 (7)c 56 7)c
Monster et al. [21] Netherlands NA Cross-sectional 59.8 (8.6) 52.8 (6.1)d N 1245/65 198/3 NA
45.4 (7.3)e
Crespo et al. [22] USA NA Cross-sectional 40e74 1639/542 700/184 388/84
Zhang et al. [23] USA NA Cross-sectional 61.5 (7.7) 60.2 (7.3) 58 6.8) 943/569 230/111 256/108
Agarwal et al. [25] USA NA Cross-sectional 58 (7) 5 ) 312/121 179/45
van Genugten et al. [26] USA NA Cross-sectional 65.7 (10.7) 6 (9.0) 378/143 238/74
Pentti et al. [24] Finland 5 Prospective 58.1 (2.8) 57.7 (2.8) 56 2.7) 3463/90 2314/51 2706/21
Values are shown as mean (standard deviation). “Never, Past, Current” indicate ERT use status.
ERT Z estrogen replacement therapy; NA Z not applicable.
a ERT continuous use.
b Diabetic women.
c Nondiabetic women.
d ERT.
e Oral contraceptives.
Table 2 Study characteristics of combined ERT on diabetic indices in postmenopausal women.
Source Location Follow-up (m) Study design Estrogen therapy Age (y) Case (n)
Placebo ERT Placebo ERT
Andersson et al. [27] Sweden 3 Crossover E2 (2 mg/d) þ NEA (1 mg/d) 59 (5) 25
Sutherland et al. [28] New Zealand 6 Parallel CEE (0.625 mg/d) þ MPA (2.5 mg/d) 1 (8) 65 (7) 19 28
Kanaya et al. [29] USA 4.1 y Parallel CEE (0.625 mg/d) þ MPA (2.5 mg/d) 66.0 (6.3) 353 381
McKenzie et al. [30] UK 6 Parallel E2 (1 mg/d) þ NE (0.5 mg/d) 1.3 (4.8) 60.7 (5.5) 22 19
Scott et al. [33] UK 12 Parallel E2 (2 mg/d) þ NEA (1 mg/d) 61 (6) 76 74
Thunell et al. [31] Sweden 6 Crossover E2 (2 mg/d) þ NEA (1 mg/d) 62 (5.3) 23
Kernohan et al. [32] UK 3 Parallel E2 (1 mg/d) þ NE (0.5 mg/d) 2.1 (3.8) 62.2 (5.8) 14 14
Lamon-Fava et al. [34] USA 3.2 y Parallel CEE (0.625 mg/d) þ MPA (2.5 mg/d) 64 (7) 27 41
Values are shown as mean (standard deviation).
CEE Z conjugated equine estrogen; E2 Z 17beta-estradiol; MPA Z medroxyprogesterone acetate; NE Z norethisterone; NEA Z thisterone acetate.
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Figure 2. Effect of estrogen replacement therapy (ERT) on the incidence of diabetes in postmenopausal women. (A) Comparison of ERT past/current/continuous use versus
never use. (B) Comparison of ERT current/continuous use versus past/never use. Squares indicate study-specific risk estimates (size of the square reflects the study-specific
statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamonds indicate summary risk estimate with its corresponding 95% CI. (C) and (D) are the
respective funnel plots of (A) and (B).
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Figure 3. Effects of combined estrogen replacement therapy (ERT) on (A) fasting plasma glucose (mM/L) and (B) HbA1c levels in
postmenopausal women with diabetes. Squares indicate study-specific risk estimates (size of the square reflects the study-specific
statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamonds indicate summary risk estimate with its
corresponding 95% CI. (C) and (D) are the respective funnel plots of (A) and (B).
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This meta-analysis outlines the protective effect of ERT on
diabetes. Overall, ERT has an inverse association with the
incidence of diabetes. In pooled data from eight trials
[27e34] that included 1164 postmenopausal cases, com-
bined ERT decreased fasting plasma glucose and HbA1c
levels and ameliorated dyslipidemia in diabetic patients,
which should have beneficial effects on the progression of
the disease and the associated complications.
ERT is a system of medical treatment for surgically
menopausal, perimenopausal, anddto a lesser extent
dpostmenopausal women. It is based on the idea that the
treatment may prevent discomfort caused by diminishedcirculating estrogen and progesterone hormones, as in the
case of surgically or prematurely menopausal women. ERT
was initially recommended as a short-term therapy for the
treatment of menopausal symptoms. Attitudes and recom-
mendations regarding ERT have fluctuated repeatedly over
the past 50 years. During the 1990s, the preventive benefits
of ERT were believed to outweigh the risks for most women
[14]. Findings of this meta-analysis may have direct public
health importance in that low-dose combined ERT (Table 2)
may have beneficial effects on diabetes, especially in
postmenopausal women.
It has been well known that the incidence of diabetes is
higher in postmenopausal women compared with that in
premenopausal women. In this meta-analysis, we observed
Figure 4. (A) Effects of combined ERT on BMI in postmenopausal women with diabetes. Squares indicate study-specific risk
estimates (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CIs; diamonds indicate
summary risk estimate with its corresponding 95% CI. (B) The funnel plot is plotted. BMI Z body mass index; CI Z confidence
intervals; ERT Z estrogen replacement therapy.
ERT and diabetes in postmenopausal women 357a beneficial effect of ERT on diabetes in postmenopausal
women: on one hand, ERT possesses effects on preventing
new-onset diabetes, and on the other hand, it ameliorates
the diabetic symptoms. The metabolic syndrome, including
obesity, insulin resistance, and dyslipidemia, rapidly in-
creases in prevalence after menopause [15], especially in
women with diabetes. Each of the metabolic abnormalities
associated with the syndrome is interrelated and also ap-
pears to be independent risk factors for the development of
diabetes. The amelioration of metabolic syndrome seen in
patients with combined ERT suspended the development of
diabetes. This could help to explain the reduction in the
incidence of diabetes in women with ERT. It should be
noted that current/continuous ERT has a much higher
protective effect as compared with past/never use (OR,
0.57; 95% CI, 0.51e0.65).
It has been recognized that insulin has pivotal and cen-
tral effects on blood glucose regulation [36]. However, the
association between estrogen and insulin resistance has not
yet been well defined. Most reports indicated that high
doses of estrogen are associated with insulin resistance
[37,38]. In this viewpoint, a low-dose of estrogen should be
emphasized during ERT. In the present study, only trials
with low-dose estrogen were included (Table 2). An obvious
mechanism through which combined ERT may reduce the
risk of diabetes is by improving insulin sensitivity. We have
tried to systemically evaluate combined ERT on fasting
plasma insulin; however, we could not draw a final
conclusion, because only one trial [27] met our inclusion
criteria. In their study, however, Andersson and colleagues
[27] observed a dramatic reduction of fasting plasma insulin
level in a double-blind crossover study with 8 weeks
washout period. The effect of ERT on insulin might involve
estrogen receptors. This is demonstrated in that estrogenreceptor-deficient mice and humans are glucose intolerant
and hyperinsulinemic [39,40]. Further lines of evidence
indicated that the phosphatidylinositol 3-kinase and protein
kinase B [41] pathway might be an intracellular cross-talk
junction between actions of insulin and estrogen. It
should be noted that insulin sensitivity is closely related
with plasma concentration of estrogen. It has been re-
ported previously that estrogen per se augmented insulin
sensitivity at low concentrations but diminishes insulin
sensitivity at high concentrations when examined on a
pregnancy rat model [14], in which estrogen significantly
increased the glucose infusion rate at low concentrations
but had no significant effect at high concentrations. This
helps to explain the high incidence of diabetes in pregnant
women, in whom the estrogen level was apparently high
(about 10 nM). In fact, there is a report indicating that
insulin-stimulated glucose uptake was improved by estro-
gen replacement even in postmenopausal nondiabetic
women [15]; in this sense, ERT may have beneficial effect
in an entire postmenopausal women population.
Obesity has been recognized as a major risk factor for a
variety of adverse health outcomes including insulin resis-
tance, high blood pressure, fatty liver, dyslipidemia, dia-
betes, and cardiovascular diseases [35,42]. In the present
meta-analysis, we observed a reduction of BMI on admin-
istration of combined ERT in postmenopausal diabetic
women, although no statistical significance was observed.
We postulated that it should be attributed to relative few
study references included in the analysis, as lines of evi-
dence have demonstrated the positive association between
ERT and body slimness in women. It has been recognized
that a low level of estrogen will induce nutrient metabolism
changes, which may promote nutrient storage in adipose
tissue [43].
Figure 5. Effects of combined ERT on (A) plasma TC, (B) LDL, and (C) HDL levels in postmenopausal women with diabetes. Squares indicate study-specific risk estimates (size of
the square reflects the study-specific statistical weight); horizontal lines indicate 95% CIs; diamonds indicate summary risk estimate with its corresponding 95% CI. (C), (D), and (E)
are the respective funnel plots of (A), (B), and (C). CI Z confidence intervals; ERT Z estrogen replacement therapy; HDL Z high-density lipoprotein; LDL Z low-density lipo-
protein; TC Z total cholesterol; TG Z triglyceride.
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Figure 6. (A) Effects of combined ERT on plasma TG level in postmenopausal women with diabetes. Squares indicate study-
specific risk estimates (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CIs; di-
amonds indicate summary risk estimate with its corresponding 95% CI. (B) The funnel plot was plotted. CI Z confidence intervals;
ERT Z estrogen replacement therapy; TG Z triglyceride.
ERT and diabetes in postmenopausal women 359The metabolism disorder is often accompanied by dia-
betes and is a leading cause of diabetic complications. We
observed in this meta-analysis that combined ERT signifi-
cantly decreased TC and LDL, while slightly increasing the
HDL level. The precise pathogenesis of diabetic dyslipide-
mia is not known; nevertheless, a large body of evidence
suggests that insulin resistance has a central role in the
development of this condition [44]. The beneficial effect of
combined ERT on ameliorating insulin resistance as
observed by Andersson and colleagues [27] should at least
partially contribute to the amelioration of dyslipidemia in
diabetic patients. As is well known, most of the cholesterols
are synthesized in the liver, indicating that liver dysfunc-
tion may significantly affect the metabolism of choles-
terols. A strong association between diabetes and liver
diseases has been demonstrated; diabetes, as an oxidative
stress and inflammatory disease, may induce hepatocyte
damage and liver dysfunction, especially in post-
menopausal women. It is estimated that up to 75% of pa-
tients with diabetes have nonalcoholic fatty liver disease
[45]. Most recently, Unal et al. [46] found that diabetes
worsened the onset of liver damage during the
ovariectomy-induced stage in postmenopausal rats. Thus, it
is reasonable to postulate that the protective effect of ERT
on cholesterol metabolism in postmenopausal women with
diabetes should at least partially be attributed to itsprotective effect on hepatocytes. Our hypothesis was
further supported by a report from McKenzie and col-
leagues [47] that ERT could help to improve liver function in
diabetic women. However, numerous studies have also
demonstrated the direct and important effects of estrogen
on liver functions. Population-based studies showed that
nonalcoholic hepatic steatosis is less common in women
than in men. Reports suggest that antiestrogens would
double the risk of nonalcoholic steatohepatitis [48],
whereas estrogen treatment could substantially diminish
hepatic steatosis in mice unable to produce estrogens [49]
via estrogen receptor a [50]. In fact, a very recent study
from Zhu and colleagues [51] also found that estrogen
treatment after ovariectomy protected against fatty liver
and improved insulin resistance via estrogen receptor a. In
this sense, it is meaningful for normal postmenopausal
women to take ERT for the purpose of keeping healthy.
One concern during ERT therapy is the side effects of
estrogen. Studies regarding this matter are abundant.
Previously, Løkkegaard and colleagues [52] conducted a
prospective study in Denmark and found that ERT increased
the risk of ischemic heart disease among diabetic women.
Most recently, a report [53] systemically evaluated the
benefits and risks of postmenopausal hormone therapy. It is
reported in this study that combined administration with
estrogen plus progesterone was associated with a reduction
360 Y. Xu et al.for type 2 diabetes, colon cancer, overall mortality, etc.; at
the same time, low-dose and continuous combined therapy
does not cause endometrial cancer. However, it still should
be noted that ERT may increase the risk for breast cancer
[54], cholecystitis, etc.; furthermore, endocrine hormones
such as male hormones [55] may also be influenced by
combined ERT. Therefore, patients should weigh the ben-
efits against risks prior to undergoing ERT.
Several limitations of our meta-analysis must be
acknowledged. First, only articles published in the English
language were included. Limited resources prevented us
from including articles published in other languages. Second,
fasting plasma insulin level was not evaluated on adminis-
tration of combined ERT; this should be attributed to the fact
that only a few studies met our strict inclusion criteria.
Considering the fact that numerous studies have demon-
strated that ERTcould relieve insulin resistance, it should not
influence our conclusion that combined ERT could alleviate
diabetes in postmenopausal women. Lastly, the side effect
of ERTwas not evaluated in this analysis. As discussed above,
ERT may be associated with cancer and androgen effects,
etc. However, we could not source enough data from the
included references. Despite the above limitations in our
analysis, this did not influence our conclusion that combined
ERTwas inversely related with diabetes.
In conclusion, available data from the trials show that
low-dose combined ERT can reduce the incidence of dia-
betes and ameliorate diabetic indices in postmenopausal
women.
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